This is market intelligence they would share with internal stakeholders. United Therapeutics does not provide medical advice. Rothnie KJ, Bancroft T, Bogart M, et al. 1. LAG3 (CD223) as a cancer immunotherapy target. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? P713; Abstract A1828], 10. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus (SLE) Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database, 1. Mittal D, Lepletier A, Madore J, et al. P824; Abstract A4313]. [Poster No. Cultivating relationships with Key Opinion Leaders (e.g., healthcare practitioners, academic researchers, experts in defined therapeutic areas). MAPS is the premier non-profit global Medical Affairs organization FOR Medical Aairs professionals BY Medical Affairs professionals across all dierent levels of experience/specialty. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. Lee LA, Boulet LP, Fowler A, et al. 2015;23:82-91. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. This article outlines the aspects of Medical Affairs strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases, providing a roadmap for MA teams and organizations undertaking this planning. Prazma C, Bernstein D, Brightling C, et al. Syneos Health Medical Affairs provides life sciences companies with the depth and breadth of medical affairs expertise needed to optimize product development. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Das M, Zhu C, Kuchroo VK. 6. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Poster No. POSTER: Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Non-endometrial Solid Tumors: a Post Hoc Subgroup Analysis of Patients with Colorectal Cancer, 1. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin? Kerwin EM, Maltais F, Boucot IH, et al. 9. 2. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. 5. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-cell?dependent tumor immunity. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. See product details, storage & handling info for GSK vaccines, and more. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. A Nationwide Multicentric Study, 4. As described in the book Understanding Pharma: The Professionals Guide to How Pharmaceutical and Biotech Companies Really Work, when a drug emerges from clinical development and is on the cusp of commercialization, Medical Affairs will lead the effort to explain to potential healthcare prescribers the real-world applications of the drug through the dissemination of unbiased clinical and scientific information. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Medical Affairs Genmab is an international biotechnology company with a core purpose of improving the lives of people with cancer. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. P574]. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. POSTER: First-line (1L) Maintenance Therapy with Niraparib + Pembrolizumab vs Placebo + Pembrolizumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): Phase 3 ZEAL-1L Study, 4. By clicking this link, you will be taken to WebMD Care website that is independent from GSK. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. 9. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Eur J Immunol. and physicians? Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. ORAL PRESENTATION: Satram S, et al. 7. Wu AC, McMahon PM, Mendelsohn A, et al. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. 1. 13. Welcome to United Therapeutics Global Medical Affairs This website is a resource intended for U.S. healthcare professionals only. CAPTAIN study: Effects of baseline IgE levels on triple therapy response in inadequately controlled asthma. [Abstract/Poster No. Gathering and sharing market intelligence. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. Slade D, Ray R, Moretz C, et al. 805; Abstract A4294]. [Poster No. 4. Myovant Medical Affairs This website is intended to provide balanced, scientific, and evidence-based medical information to U.S. healthcare providers. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? ?trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. The Impact of Baseline Exhaled Nitric Oxide Levels and Blood Eosinophil Count on Clinical Outcomes in REALITI-A. A Population Study. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. 7. P786; Abstract A5624]. The products discussed may have different product labeling in different countries. Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo Controlled Studies, 7. 2014;123(20):3128-3138. and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. 3. about disease states including Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa. ORAL PRESENTATION: DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin plus Inducible T cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma, 1. PO1437, 2. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. 14. VAT no. P474; Abstract A3997]. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. 2016;126(7):2404-2411. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Moretz C, Hahn B, White J, et al. Singh AK, et al. Poster No. and PD-L1 pathways. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. My Medical Affairs (MyMA)provides you with one central place to keep up to date with all the upcoming events relevant to your medical affairs interests, from a plethora of organizations around the globe. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study. Gibbons D, Marijam A, Symons JM, et al. Criner GJ, Barnes N, Brusselle G, et al. P1458. 5. Poster No. 2. Medical affairs' primary goal is to educate and equip both medical sales force and healthcare providers with unbiased and necessary scientific information. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability?high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1. 1. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out? CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. Bogart M, Han X, Bengtson L, et al. It is being studied as a monotherapy in advanced NY-ESO-1? This website was developed by Paratek Medical Affairs professionals as a resource for healthcare professionals practicing in the United States. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. Discover resources and support for healthcare professionals with GSK US Medical Affairs. [Poster No. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, ASCEND program: efficacy and safety from ASCEND-D and ?ND, and overall MACE findings, Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. To report suspected adverse events or product complaints in the United States, please call 1-877-411-2510 (option #1) or email medinfoUS@covispharma.com (option #2). Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Please confirm the option below that best describes you: You are now leaving Genmab Medical Affairs. BCMA is essential for the survival of long-lived bone marrow plasma cells. P481]. 1. [Poster No. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Belimumab Improves Renal Responses in Patients With or Without Steroid Pulses During Induction Therapy for Lupus Nephritis, 1. Prez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. 6. This site is intended for US healthcare professionals only. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell?mediated immune responses. 2. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States ? POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Phone +45 7020 2728, CVR no. Immunol Rev. Asthma control among the treated U.S. asthma population in Practice Fusion?s Electronic Medical Record Research Database, 2015-2018. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. 307 East First Street, Suite 20 Poster No. POSTER: Survival in patients (pts) with advanced ovarian cancer (AOC) changes with cumulative number of risk factors (RFs), a US real-world (RW) analysis, 6. Association between TGF-? POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Silver J, Bogart M, Molfino N, et al. ORAL PRESENTATION: Shapiro A, et al. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. J Clin Invest. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations.
Reverend Parris' Daughter, Ryobi 3200 Psi Pressure Washer Spark Plug, Gary Danko Sf Dress Code, Skywalker Saga Smuggling Glitch, South Kingstown Fireworks, % Increase Formula Excel,